Abstract:The liver is a critical system for metabolism in human beings, which plays an essential role in an abundance of physiological processes and is vulnerable to endogenous or exogenous injuries. After the damage to the liver, a type of aberrant wound healing response known as liver fibrosis may happen, which can result in an excessive accumulation of extracellular matrix (ECM) and then cause cirrhosis or hepatocellular carcinoma (HCC), seriously endangering human health and causing a great economic burden. However, few effective anti-fibrotic medications are clinically available to treat liver fibrosis. The most efficient approach to liver fibrosis prevention and treatment currently is to eliminate its causes, but this approach’s efficiency is too slow, or some causes cannot be fully eliminated, which causes liver fibrosis to worsen. In cases of advanced fibrosis, the only available treatment is liver transplantation. Therefore, new treatments or therapeutic agents need to be explored to stop the further development of early liver fibrosis or to reverse the fibrosis process to achieve liver fibrosis resolution. Understanding the mechanisms that lead to the development of liver fibrosis is necessary to find new therapeutic targets and drugs. The complex process of liver fibrosis is regulated by a variety of cells and cytokines, among which hepatic stellate cells (HSCs) are the essential cells, and their continued activation will lead to further progression of liver fibrosis. It has been found that inhibiting HSC activation, or inducing apoptosis, and inactivating activated hepatic stellate cells (aHSCs) can reverse fibrosis and thus achieve liver fibrosis regression. Hence, this review will concentrate on how HSCs become activated during liver fibrosis, including intercellular interactions and related signaling pathways, as well as targeting HSCs or liver fibrosis signaling pathways to achieve the resolution of liver fibrosis. Finally, new therapeutic compounds targeting liver fibrosis are summarized to provide more options for the therapy of liver fibrosis.

Research Advances in Immune Cellular Pathogenesis in Liver Fibrosis

Regulatory Long Non-Coding RNAs of Hepatic Stellate Cells in Liver Fibrosis (Review)

Research progress on roles of immune factors in development of hepatic fibrosis

Liver fibrosis: mechanisms of immune-mediated liver injury

Novel Immune Subsets and Related Cytokines: Emerging Players in the Progression of Liver Fibrosis

[Research Advances in the Treatment of Hepatic Fibrosis].

Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets

Ongoing involvers and promising therapeutic targets of hepatic fibrosis: The hepatic immune microenvironment

Liver Fibrosis in Fish Research: from an Immunological Perspective

Cellular Mechanisms in Liver Fibrosis Regression

Research progression on the activation of hepatic stellate cells

Liver Fibrosis Resolution: from Molecular Mechanisms to Therapeutic Opportunities

Crosstalk Between Autophagy and Innate Immunity: A Pivotal Role in Hepatic Fibrosis

Activation and Inhibition of Human HSCs and the Related Molecular Mechanisms

Immunoregulation of Liver Fibrosis: New Opportunities for Antifibrotic Therapy

Intercellular crosstalk of hepatic stellate cells in liver fibrosis: New insights into therapy

Liver Fibrosis: Therapeutic Targets and Advances in Drug Therapy

Novel insights into the role of immunomodulatory extracellular vesicles in the pathogenesis of liver fibrosis

Recent perspectives on mechanisms of liver fibrogenesis: microRNA and cell autophagy

Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: An update

Liver Disease: Induction, Progression, Immunological Mechanisms, and Therapeutic Interventions